InspiroGene by McKesson Partners With Vertex To Expand Distribution Of CASGEVY, The First FDA-Approved CRISPR Gene-Editing Therapy For Sickle Cell Disease And Β-Thalassemia
InspiroGene by McKesson Partners With Vertex To Expand Distribution Of CASGEVY, The First FDA-Approved CRISPR Gene-Editing Therapy For Sickle Cell Disease And Β-Thalassemia
麥克森的InspiroGene與Vertex合作,擴大CASGEVY的分發範圍,這是第一個獲得FDA批准的用於鐮狀細胞病和Β-地中海貧血的CRISPR基因編輯療法。
InspiroGene by McKesson Partners With Vertex To Expand Distribution Of CASGEVY, The First FDA-Approved CRISPR Gene-Editing Therapy For Sickle Cell Disease And Β-Thalassemia
麥克森旗下的InspiroGene與vertex合作,擴大CASGEVY的分銷,這是首個獲得FDA批准的針對鐮狀細胞病和β-地中海貧血的CRISPR基因編輯療法。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。